Aripiprazole lauroxil vs. Abilify Maintena

Discussion in 'Alkermes' started by Anonymous, Jul 16, 2014 at 1:27 AM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    What is the difference between these two products that will make a difference to doctors?
     

  2. Anonymous

    Anonymous Guest

    Consultting Company or competitive troll alert. DO NOT ANSWER!!!!
     
  3. Anonymous

    Anonymous Guest

    Looks like someone needs a spelling consultant. The OP does have a good point. I am surprised no one answered their question.
     
  4. Anonymous

    Anonymous Guest

    Easier to use and PRICE!!! The end is near for MAINTENA!
     
  5. Anonymous

    Anonymous Guest

    How is it "easier to use and price"?
     
  6. Anonymous

    Anonymous Guest

    A deltoid and gluteal vs gluteal + prefilled syringe + 1000.00 doolars/ dose.= Medicaid and Part D and Managed Care advantage = Death for Maintena!
     
  7. Anonymous

    Anonymous Guest

    I'll give you the first two. Your dose price and reimbursement advantage is horse crap and you my friend are full of it. We have been selling for a year and the market has spoken. Abilify is not the injectable choice for treating schizophrenia, that position belons to Sustenna. With out any further indications you're going nowhere. Even with that, ask Janssen how an injectable for bipolar 1 maintenance is going.
     
  8. Anonymous

    Anonymous Guest

    Right:) good luck with your me too drug. You know nothing about these patients who don't even come back or take their medicine. Nevermind the managed care issues. Enjoy your high salary because after Big Pharma buys you out, you'll all be working for Jannsen in a year or downsized all together.
     
  9. Anonymous

    Anonymous Guest

    We have no idea about patients that only show up for one dose and navigating managed care coverage. too funny
     
  10. Anonymous

    Anonymous Guest

    You are too funny dude! Do you know that Alkermes makes both Consta and Sustenna for Jansen.. Got to me a dumbass rep for Otsuka
     
  11. Anonymous

    Anonymous Guest

    Easy buy out for Jansen/JNJ! Makes great sense
     
  12. Anonymous

    Anonymous Guest

    definitely a clueless Otsuka rep who still believes in their ability to market maintena. alkermes if they play their cards right, will be able to build on the little progress made by otsuka and market their development of Sustenna and Consta.
     
  13. Anonymous

    Anonymous Guest

    this is funny- which abilify injection is better the one from otsuka or the one from alkermes? silly little trolls! neither will do much of anything and alkermes will be waiting to launch because of the recent petition from otsuka to the fda. alkermes will need to conduct another clinical trial will be the findings because of molecular differences and they only conducted 1- FDA says you need 2 so it will be another 2 years before alkermes product is even considered for approval. ba boom!
     
  14. Anonymous

    Anonymous Guest

    Talk about an idiot troll! Ba ba boom!
     
  15. Anonymous

    Anonymous Guest

    ok alkermes man! dont be frustrated cause the disappointment. it happens.
    fill us in on what "leadership" is saying regarding the expansion and new
    positions in CNS! I bet its awfully quiet over there.....tick tock and then BA BOOM
     
  16. Anonymous

    Anonymous Guest

    Easy big boy. Just because your company is pulling a desperate Hail Mary because you are scared does not mean it will work. Also. At your rate of biz $150M in a year is not exactly an Oscar performance. So get over yourself and go hate somewhere else
     
  17. Anonymous

    Anonymous Guest

    Funny to see someone taking offense to a me too med that isn't approved yet.
    I guess you plan on being hired?
     
  18. Anonymous

    Anonymous Guest

    Buyout approaching. The company will not be around much longer
     
  19. Anonymous

    Anonymous Guest

    Heard it was going to be J&J
     
  20. anonymous

    anonymous Guest